Pharma pivots to accelerate oncology antibodies and subcutaneous delivery; Sanofi assesses impact

Pharma pivoting to speed oncology antibodies and simplify delivery

Regulatory accelerants and subcutaneous delivery are reshaping how big drugmakers advance antibody therapies, a shift that is closely watched by Sanofi as it refines its biologics and oncology strategy. Companies increasingly seek FDA Breakthrough Therapy designations to shorten development timelines for promising cancer antibodies, while striking partnerships with specialist firms that provide hyaluronidase-based delivery technology to convert intravenous biologics into subcutaneous formulations. The combination of regulatory acceleration and delivery innovation is allowing developers to focus on patient convenience, outpatient care pathways and more rapid market access.

The industry is adopting enzyme-enabled subcutaneous delivery to reduce infusion times and clinic burden, with Halozyme’s Enhanze (recombinant human hyaluronidase) cited widely as an enabler for this approach. Drugmakers pursuing oncology antibodies are testing subcutaneous versions to improve dosing flexibility and broaden treatment settings beyond infusion centers. That trend is evident in recent collaboration patterns between large pharmas and delivery-platform biotechs, where the technical work centers on maintaining efficacy and safety while achieving more convenient administration.

Sanofi, with an established footprint in biologics and oncology, is positioned to be affected by these developments and is likely assessing similar pathways for its antibody portfolio. The company is monitoring how Breakthrough Therapy designations and delivery partnerships alter clinical development priorities, patient-support needs and hospital versus home-care treatment models. For Sanofi’s research and commercial teams, the industry shift underscores the importance of integrating regulatory strategy with formulation and device innovation early in development.

Other industry moves

Beyond delivery platforms, firms are increasingly structuring collaborations that pair discovery and clinical scale capabilities with niche technology providers, reflecting a broader outsourcing of specialized formulation work. This modular approach speeds iterations and lets large companies concentrate on core discovery and global commercialization.

Regulator focus and next steps

Regulators are balancing faster access with rigorous evaluation of safety and long-term outcomes for reformulated biologics, meaning companies must present robust comparability data. As the sector adopts subcutaneous formats and pursues expedited pathways, regulatory engagement and clear clinical endpoints remain central to successful approvals.